Patent US3873433A successfully refreshed from Google Patents.
← Back to Patent Explorer
US3873433A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of demonstrating normal and pathological plasm-lipoprotein patterns in human body liquids

Assignee: Oesterreichisches Institut fuer Haemoderivate
•
Filing: 1973-12-19
•
Granted: 1975-03-25
•
Expires: 1993-12-19
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for the demonstration of normal and pathological plasmlipoprotein patterns in human body liquids by electrophoretical separation of the lipoproteins in a carrier medium, such as a gel, or on foils, which consists in that after the desired electrophoretical separation effect has been achieved the carrier is treated with a developing solution comprising polyanions, and an apparatus for carrying out the method.

Inventors

  • 👤 Dietrich Seidel
  • 👤 Heinrich Wieland
  • 👤 Johann Eibl
  • 👤 Gerald Eder
  • 👤 Ewald Molinari

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 13:53
CPC Classifications
G; G01; G01N; G01N27/00; G01N27/26; G01N27/416; G01N27/447; G01N27/44704; G01N27/44717; G01N27/44721; G01N27/44726

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 69 words
A METHOD OF DEMONSTRATING NORMAL AND PATHOLOGICAL PLASMA-LIPOPROTEIN PATTERNS IN HUMAN BODY LIQUIDS WHICH COMPRISES ELECTROPHORETICALLY SEPARATING LIPOPROTEINS IN A CARRIER MEDIUM OR ON FOILS, UPON OCCURRENCE OF A DESIRED ELECTROPHORETICAL SEPARATION EFFECT, TREATING THE CARRIER WITH A DEVELOPING SOLUTION, COMPRISING AT LEAST ONE OF THE FOLLOWING SUBSTANCES: POLYANIONS, SELECTED FROM THE GROUP CONSISTING OF HEPARIN AND DEXTRAN SULFATE, SODIUM-DODECYL-SULFATE (SOS), SODIUMPHOSPHOTUNGSTIC ACID, SODIUM OLEATE, SODIUM SALTS OF BILE
Claim 2
Independent Claim 69 words
A METHOD OF DEMONSTRATING NORMAL AND PATHOLOGICAL PLASMA-LIPOPROTEIN PATTERNS IN HUMAN BODY LIQUIDS WHICH COMPRISES ELECTROPHORETICALLY SEPARATING LIPOPROTEINS IN A CARRIER MEDIUM OR ON FOILS, UPON OCCURRENCE OF A DESIRED ELECTROPHORETICAL SEPARATION EFFECT, TREATING THE CARRIER WITH A DEVELOPING SOLUTION, COMPRISING AT LEAST ONE OF THE FOLLOWING SUBSTANCES: POLYANIONS, SELECTED FROM THE GROUP CONSISTING OF HEPARIN AND DEXTRAN SULFATE, SODIUM-DODECYL-SULFATE (SOS), SODIUMPHOSPHOTUNGSTIC ACID, SODIUM OLEATE, SODIUM SALTS OF BILE
Claim 3
Dependent Claim 13 words
A method according to claim 1, wherein the carrier medium is a gel.
Claim 4
Dependent Claim 25 words
A method according to claim 1, wherein bivalent cations, selected from the group consisting of magnesium and calcium, are additionally present in the developing solution.
Claim 5
Dependent Claim 21 words
A method according to claim 1, wherein for demonstrating LP-X-lipoprotein, a developing solution is used which comprises heparin and magnesium ions.
Claim 6
Dependent Claim 14 words
A method according to claim 4, wherein the developing solution additionally contains sodium chloride.
Claim 7
Dependent Claim 23 words
A method according to claim 1, wherein for demonstrating lipoprotein type III a developing solution is used whiCh comprises heparin and magnesium ions.
Claim 8
Dependent Claim 14 words
A method according to claim 6, wherein the developing solution additionally contains sodium chloride.
Claim 9
Dependent Claim 54 words
A method according to claim 1, wherein for selectively demonstrating lipoprotein type III and lipoproteins VLDL, LDL and HDL the carrier is successively treated with a first developing solution and a second developing solution, the first developing solution comprising heparin and magnesium ions and the second developing solution comprising dextran sulfate and calcium ions.
Claim 10
Dependent Claim 25 words
A method according to claim 1, wherein for demonstrating lipoprotein LP-X a carrier is used which already contains at least parts of the developing solution.
Claim 11
Dependent Claim 13 words
A method according to claim 9, wherein the carrier is a gel plate.

References Cited (Backward Citations)

US3783118A Cited
US3773647A Cited
US3766047A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1978-03-24 1978-09-23 1979-03-25 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1982-03-24 1982-09-23 1983-03-25 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1986-03-24 1986-09-23 1987-03-25 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag